Literature DB >> 993332

An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity.

J P Kushner, A J Barbuto, G R Lee.   

Abstract

Uroporphyrinogen decarboxylase activity was measured in liver and erythrocytes of normal subjects and in patients with porphyria cutanea tarda and their relatives. In patients with porphyria cutanea tarda, hepatic uroporphyrinogen decarboxylase activity was significantly reduced (mean 0.43 U/mg protein; range 0.25-0.99) as compared to normal subjects (mean 1.61 U/mg protein; range 1.27-2.42). Erythrocyte uroporphyrinogen decarboxylase was also decreased in patients with porphyria cutanea tarda. The mean erythrocyte enzymatic activity in male patients was 0.23 U/mg Hb (range 0.16-0.30) and in female patients was 0.17 U/mg Hb (range 0.15-0.18) as compared with mean values in normal subjects of 0.38 U/mg Hb (range 0.33-0.45) in men and 0.26 U/mg Hb (range 0.18-0.36) in women. With the erythrocyte assay, multiple examples of decreased uroporphyrinogen decarboxylase activity were detected in members of three families of patients with porphyria cutanea tarda. In two of these families subclinical porphyria was also recognized. The inheritance pattern was consistant with an autosomal dominant trait. The difference in erythrocyte enzymatic activity between men and women was not explained but could have been due to estrogens. This possibility was supported by the observation that men under therapy with estrogens for carcinoma of the prostate had values in the normal female range. It is proposed that porphyria cutanea tarda results from the combination of an inherited defect in uroporphyrinogen decarboxylase and an acquired factor, usually siderosis associated with alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993332      PMCID: PMC333275          DOI: 10.1172/JCI108560

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Porphyria cutanea tarda associated with disinfectant misuse.

Authors:  R E Lynch; G R Lee; J P Kushner
Journal:  Arch Intern Med       Date:  1975-04

2.  PORPHYRIA CUTANEA TARDA ASSOCIATED WITH OESTROGEN THERAPY FOR PROSTATIC CARCINOMA.

Authors:  R P WARIN
Journal:  Br J Dermatol       Date:  1963-07       Impact factor: 9.302

3.  The problem of porphyria--some facts and questions.

Authors:  C J WATSON
Journal:  N Engl J Med       Date:  1960-12-15       Impact factor: 91.245

4.  Porphyrin biosynthesis in erythrocytes. III. Uroporphyrinogen and its decarboxylase.

Authors:  D MAUZERALL; S GRANICK
Journal:  J Biol Chem       Date:  1958-06       Impact factor: 5.157

5.  The enzymatic synthesis of porphyrins from porphobilinogen. III. Uroporphyrinogens as intermediates.

Authors:  L BOGORAD
Journal:  J Biol Chem       Date:  1958-08       Impact factor: 5.157

6.  The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase.

Authors:  J P Kushner; D P Steinmuller; G R Lee
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

7.  Diminished erythroid ferrochelatase activity in protoporphyria.

Authors:  S S Bottomley; M Tanaka; M A Everett
Journal:  J Lab Clin Med       Date:  1975-07

8.  Alcohol-induced testicular atrophy. An experimental model for hypogonadism occurring in chronic alcoholic men.

Authors:  D H Van Thiel; J S Gavaler; R Lester; M D Goodman
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

9.  Studies of the uroporphyrins. III. An improved method for the decarboxylation of uroporphyrin.

Authors:  P R EDMONDSON; S SCHWARTZ
Journal:  J Biol Chem       Date:  1953-12       Impact factor: 5.157

10.  Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts.

Authors:  H L Bonkowsky; J R Bloomer; P S Ebert; M J Mahoney
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

View more
  48 in total

1.  Steady-state levels of uroporphyrinogen decarboxylase mRNA in lymphoblastoid cell lines from patients with familial porphyria cutanea tarda and their relatives.

Authors:  J L Hansen; M A Pryor; J B Kennedy; J P Kushner
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

2.  The effects in vivo of mutationally modified uroporphyrinogen decarboxylase in different hem12 mutants of baker's yeast (Saccharomyces cerevisiae).

Authors:  A Kurlandzka; T Zoladek; J Rytka; R Labbe-Bois; D Urban-Grimal
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

3.  Decarboxylation of uroporphyrinogen III by erythrocyte uroporphyrinogen decarboxylase. Evidence for a random decarboxylation mechanism.

Authors:  J Luo; C K Lim
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

4.  Crystal structure of human uroporphyrinogen decarboxylase.

Authors:  F G Whitby; J D Phillips; J P Kushner; C P Hill
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

5.  Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria.

Authors:  H de Verneuil; C Beaumont; J C Deybach; Y Nordmann; Z Sfar; R Kastally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

6.  Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome 1 by somatic cell hybridization and specific enzyme immunoassay.

Authors:  H de Verneuil; B Grandchamp; C Foubert; D Weil; V C N'Guyen; M S Gross; S Sassa; Y Nordmann
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

7.  Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles.

Authors:  M Mendez; L Sorkin; M V Rossetti; K H Astrin; A M del C Batlle; V E Parera; G Aizencang; R J Desnick
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  A radiochemical method for the measurement of coproporphyrinogen oxidase and the utilization of substrates other than coproporphyrinogen III by the enzyme from rat liver.

Authors:  G H Elder; J O Evans
Journal:  Biochem J       Date:  1978-01-01       Impact factor: 3.857

9.  Factors determining the sequence of oxidative decarboxylation of the 2- and 4-propionate substituents of coproporphyrinogen III by coproporphyrinogen oxidase in rat liver.

Authors:  G H Elder; J O Evans; J R Jackson; A H Jackson
Journal:  Biochem J       Date:  1978-01-01       Impact factor: 3.857

10.  Incidence of hereditary porphyria cutanea tarda (PCT) in a sample of the Italian population.

Authors:  L D'Alessandro; D Griso; G Biolcati; A Macrì; G C Topi
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.